Oxford Bio Therapeutics
Biotechnology, 5941 Optical Ct, Oxford, California, 95138, United States, 11-50 Employees
Phone Number: 40********
Who is OXFORD BIOTHERAPEUTICS
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and ant...
Read More
-
Headquarters: 5941 Optical Ct, Oxford, California, 95138, United States
-
Date Founded: 2004
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from OXFORD BIOTHERAPEUTICS
Oxford BioTherapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Oxford BioTherapeutics
Answer: Oxford BioTherapeutics's headquarters are located at 5941 Optical Ct, Oxford, California, 95138, United States
Answer: Oxford BioTherapeutics's phone number is 40********
Answer: Oxford BioTherapeutics's official website is https://oxfordbiotherapeutics.com
Answer: Oxford BioTherapeutics's revenue is $1 Million to $5 Million
Answer: Oxford BioTherapeutics's SIC: 2834
Answer: Oxford BioTherapeutics's NAICS: 325412
Answer: Oxford BioTherapeutics has 11-50 employees
Answer: Oxford BioTherapeutics is in Biotechnology
Answer: Oxford BioTherapeutics contact info: Phone number: 40******** Website: https://oxfordbiotherapeutics.com
Answer: Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBTs proprietary OGAP target discovery platform is based on one of the worlds largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. The companys pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month